Prospective, Randomized, Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus-eluting Stent
A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 585 participants.
Also called NCT01939249
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 585 participants
- Sponsor
- Registry
-
NCT01939249
-
- Other papers using this trial's data
- BIOFLOW-IV, a randomised, intercontinental, multicentre study to assess the safety and effectiveness of the Orsiro sirolimus-eluting stent in the treatment of subjects with de novo coronary artery lesions: primary outcome target vessel failure at 12 months
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- Australia, Belgium, Denmark, Germany, Israel, Japan, Netherlands, New Zealand, Poland, Spain, Sweden, Switzerland
- Registry status
- Unknown status
Technical summary
Registry record NCT01939249. Randomized; no masking; primary purpose treatment. Start 2013-09 (registry gives no type); primary completion 2016-03-23 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Prospective, Randomized, Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus-eluting Stent
- Acronym
- BIOFLOW-IV
- Condition
- Coronary Artery Disease
- Intervention (Device)
- Abbott Laboratories Xience
- Intervention (Device)
- Biotronik Orsiro
- Lead sponsor
- Biotronik AG
Record details
- Record id
cardio:ct-nct01939249- Content hash
80100ae1b4fb804ff221fbd90fe7715f43a6d927431e5ab775c1d27737fa37ee